Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Abstract

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).

Keywords

Affiliated Institutions

• Oncology Hematology Care US
• Sarah Cannon US
• The Netherlands Cancer Institute NL
• Centro de Estudios Científicos CL
• University Hospital Heidelberg DE
• Fondazione IRCCS Istituto Nazionale dei Tumori IT
• Erasmus MC Cancer Institute NL
• Sidney Kimmel Comprehensive Cancer Center US
• Russian Cancer Research Center NN Blokhin RU
• City of Hope US
• Massachusetts General Hospital US
• Hospital Universitario Virgen del Rocío ES
• University of Duisburg-Essen DE
• University of Chicago US
• Bristol-Myers Squibb (United States) US
• Duke Medical Center US
• Ruhrlandklinik DE
• University of Perugia IT
• Hospital Universitario Fundación Jiménez Díaz ES
• Hospital Universitario HM Sanchinarro ES
• Moffitt Cancer Center US
• Amphia Ziekenhuis NL
• Tennessee Oncology US
• Fakultní nemocnice Bulovka CZ
• Centrum Onkologii PL
• Heidelberg University DE
• LungenClinic Grosshansdorf DE

Related Publications